CA2719523C - Polymorphic forms of 4-phenylamino quinazoline derivatives, the preparation methods and uses thereof - Google Patents

Polymorphic forms of 4-phenylamino quinazoline derivatives, the preparation methods and uses thereof Download PDF

Info

Publication number
CA2719523C
CA2719523C CA2719523A CA2719523A CA2719523C CA 2719523 C CA2719523 C CA 2719523C CA 2719523 A CA2719523 A CA 2719523A CA 2719523 A CA2719523 A CA 2719523A CA 2719523 C CA2719523 C CA 2719523C
Authority
CA
Canada
Prior art keywords
crystalline form
solution
mixture
chloro
benzyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2719523A
Other languages
English (en)
French (fr)
Other versions
CA2719523A1 (en
Inventor
Jianhui Guo
Yong Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Pharmaceuticals Inc
Original Assignee
Shanghai Allist Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Inc filed Critical Shanghai Allist Pharmaceuticals Inc
Publication of CA2719523A1 publication Critical patent/CA2719523A1/en
Application granted granted Critical
Publication of CA2719523C publication Critical patent/CA2719523C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2719523A 2008-03-25 2009-03-25 Polymorphic forms of 4-phenylamino quinazoline derivatives, the preparation methods and uses thereof Active CA2719523C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200810043189.7 2008-03-25
CN200810043189A CN101544609A (zh) 2008-03-25 2008-03-25 4-苯胺喹唑啉衍生物的结晶形式
PCT/CN2009/000317 WO2009117899A1 (zh) 2008-03-25 2009-03-25 4-苯胺喹唑啉衍生物多晶型物及其制法和应用

Publications (2)

Publication Number Publication Date
CA2719523A1 CA2719523A1 (en) 2010-09-24
CA2719523C true CA2719523C (en) 2016-07-19

Family

ID=41112941

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2719523A Active CA2719523C (en) 2008-03-25 2009-03-25 Polymorphic forms of 4-phenylamino quinazoline derivatives, the preparation methods and uses thereof

Country Status (8)

Country Link
US (3) US8338438B2 (https=)
EP (1) EP2269994B1 (https=)
JP (1) JP5460689B2 (https=)
KR (1) KR101579148B1 (https=)
CN (4) CN101544609A (https=)
AU (1) AU2009229433B2 (https=)
CA (1) CA2719523C (https=)
WO (1) WO2009117899A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN104558041B (zh) * 2015-01-30 2017-01-11 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
CN104558040B (zh) * 2015-01-30 2017-04-05 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的晶型及其制备方法和应用
CN104558043B (zh) * 2015-01-30 2017-01-11 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
CN104610364B (zh) * 2015-01-30 2017-03-29 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
CN104558042B (zh) * 2015-01-30 2017-03-29 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
JP2019521175A (ja) * 2016-07-22 2019-07-25 メッドシャイン ディスカバリー インコーポレイテッド ニトロイミダゾール系化合物の結晶形、塩形およびその製造方法
JP7191446B2 (ja) * 2017-01-30 2022-12-19 塩野義製薬株式会社 キナゾリン誘導体を含有する固形製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9707453A (es) 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
AU5391099A (en) 1998-07-30 2000-02-21 American Home Products Corporation Substituted quinazoline derivatives
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
CN101003514A (zh) * 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
CN101245050A (zh) * 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-苯胺喹唑啉衍生物的盐

Also Published As

Publication number Publication date
EP2269994A1 (en) 2011-01-05
JP5460689B2 (ja) 2014-04-02
US8338438B2 (en) 2012-12-25
CN102007104B (zh) 2014-02-19
CN103420925A (zh) 2013-12-04
CN103382183B (zh) 2014-11-12
CN101544609A (zh) 2009-09-30
CN102007104A (zh) 2011-04-06
CN103382183A (zh) 2013-11-06
US20120004249A1 (en) 2012-01-05
CN103420925B (zh) 2014-11-12
JP2011515421A (ja) 2011-05-19
AU2009229433B2 (en) 2013-08-15
US20150133476A1 (en) 2015-05-14
AU2009229433A1 (en) 2009-10-01
US8937079B2 (en) 2015-01-20
WO2009117899A1 (zh) 2009-10-01
CA2719523A1 (en) 2010-09-24
KR20110040746A (ko) 2011-04-20
US20130137711A1 (en) 2013-05-30
EP2269994A4 (en) 2011-03-23
US9102629B2 (en) 2015-08-11
KR101579148B1 (ko) 2015-12-21
EP2269994B1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
US9102629B2 (en) Polymorphic forms of 4-phenylamine quinazoline derivative, the preparation method and uses thereof
EP1990337A1 (en) Quinazoline derivatives,preparation methods and uses thereof
MXPA06004076A (es) Proceso para la preparacion de compuestos de aminocrotonilo.
CA2677978C (en) Salts forms of 4-phenylamino quinazoline derivative
CN102070618A (zh) 一种化合物及其晶体
CA2990747C (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
AU2013231084B2 (en) The polymorphs of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof
CN101932326A (zh) 4-苯胺喹唑啉衍生物的制药用途
CN1854130B (zh) 喹唑啉衍生物、及其制法和药物组合物与用途
US11111234B2 (en) Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof
WO2008046242A1 (fr) Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131205

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250102

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250102

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216